ASA Monitor May 2024, Vol. 88, 27. The U.S. Food and Drug Administration (FDA) has granted approval to Thirona’s LungQ™ AI-based clinical software, making it one of few FDA-cleared solutions able to automatically segment pulmonary structures, aiding in lung diagnosis and documentation. LungQ’s analysis improves the understanding of lung anatomy, facilitating minimally invasive treatments for diseases […]
Read MoreAuthors: George Tewfik, MD, MBA, FASA et al ASA Monitor May 2024, Vol. 88, 1–6. Postoperative cognitive dysfunction (POCD) – also referred to as perioperative neurocognitive disorders – and delirium are pathologic states that may develop after surgery and often result in distress to the patient, family members, medical practitioners, and the health care system. Patients […]
Read MoreASA Monitor May 2024, Vol. 88, 27. A 16-week clinical trial conducted by the National Institutes of Health (NIH) showcased promising results for the monoclonal antibody, omalizumab, in reducing allergic reactions to multiple foods among children ages 1 year and older with food allergies. The trial revealed that nearly 67% of participants who underwent omalizumab treatment […]
Read MoreAuthors: Christopher Fadumiye, MD, FASA et al ASA Monitor June 2024, Vol. 88, 30. Implementation of curricula is constantly evolving, supporting improvements in the quality of medical education and clinical practice (Eur J Anaesthesiol 2019;36:473-6). Evolution within medical education in anesthesiology reflects many factors, including changes in the health care environment and the role of the physician, […]
Read MoreAuthors: Debnath Chatterjee, MD, FAAP, FASA; Viviane Nasr, MD, MPH, FASA ASA Monitor May 2024, Vol. 88, 22–23. Perioperative risk stratification is an integral part of informed consent and medical decision-making processes. It also guides resource allocation and appropriate escalation of care, such as transfer to intensive care settings or tertiary-care hospitals. Fortunately, the incidence of perioperative […]
Read More